Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: heltzen

EXOZ gets $2 Million NIH Grant to Advance Cannabinoids for Drug Discovery
heltzenpress releaseinvestormedicinesciencecannabinoidskorman
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug DiscoveryJune 24, 2026
WTR Healthcare Happenings
heltzennutraceuticalspress clippingspodcastNCT
WTR podcast: Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free BiomanufacturingMay 6, 2026
Podcast: CEO Heltzen @ Executive Insights for Life Sciences Innovators
heltzenpress clippingsvideopodcast
Podcast: CEO Heltzen @ Executive Insights for Life Sciences InnovatorsApril 20, 2026
Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen
heltzenpress clippingsvideopodcast
Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael HeltzenApril 13, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
100× scale-up of NCT production achieved
heltzenpress releaseinvestornutraceuticalsmedicineNCTkorman
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideoNCTcannabinoids
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
Previous page
Page 1 of 3
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark